Aptevo Therapeutics (NASDAQ:APVO) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.07, MarketWatch Earnings reports. The business had revenue of $6.83 million for the quarter, compared to analyst estimates of $4.17 million.
Aptevo Therapeutics traded up $0.46, hitting $4.96, during mid-day trading on Friday, MarketBeat.com reports. The stock had a trading volume of 4,855 shares, compared to its average volume of 119,438. The company has a debt-to-equity ratio of 0.20, a current ratio of 4.47 and a quick ratio of 4.39. Aptevo Therapeutics has a 1-year low of $1.15 and a 1-year high of $6.35. The firm has a market cap of $101.86 million, a P/E ratio of -2.94 and a beta of 0.21.
Several research analysts recently weighed in on APVO shares. ValuEngine lowered Aptevo Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, July 30th. Zacks Investment Research lowered Aptevo Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, July 10th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $11.00 target price on shares of Aptevo Therapeutics in a research report on Friday.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.
Recommended Story: Short Selling – Explanation For Shorting Stocks
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.